Get the Stockscreener App
2.48
3.13%
-0.08
Allogene Therapeutics Inc stock is traded at $2.48, with a volume of 4.32M.
It is down -3.13% in the last 24 hours and down -6.42% over the past month.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
See More
Previous Close:
$2.56
Open:
$2.48
24h Volume:
4.32M
Relative Volume:
0.76
Market Cap:
$604.57M
Revenue:
$22,000
Net Income/Loss:
$-190.89M
P/E Ratio:
-2.8565
EPS:
-0.8682
Net Cash Flow:
$-149.63M
1W Performance:
+2.90%
1M Performance:
-6.42%
6M Performance:
+92.25%
1Y Performance:
+72.22%
1-Day Range:
$2.45
$2.66
1-Week Range:
$2.20
$2.67
52-Week Range:
$0.8621
$2.80
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Name
Allogene Therapeutics Inc
Sector
Industry
Phone
(650) 457-2700
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
2.48 | 604.57M | 22,000 | -190.89M | -149.63M | -0.8682 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Oct-10-25 | Downgrade | JP Morgan | Neutral → Underweight |
| May-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Mar-14-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Aug-08-24 | Resumed | Oppenheimer | Outperform |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| Jan-05-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Jan-24-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-06-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-12-22 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-15-22 | Upgrade | Goldman | Neutral → Buy |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-28-22 | Reiterated | B. Riley Securities | Buy |
| Oct-20-21 | Initiated | Cowen | Outperform |
| Oct-08-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-21 | Downgrade | Stifel | Buy → Hold |
| Sep-23-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-21-21 | Resumed | Jefferies | Buy |
| May-20-21 | Upgrade | Truist | Hold → Buy |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Jan-26-21 | Upgrade | Stifel | Hold → Buy |
| Dec-10-20 | Resumed | H.C. Wainwright | Buy |
| Nov-24-20 | Initiated | BofA Securities | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Jun-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-29-20 | Reiterated | H.C. Wainwright | Buy |
| May-19-20 | Upgrade | ROTH Capital | Neutral → Buy |
| May-15-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| May-14-20 | Downgrade | SunTrust | Buy → Hold |
| Apr-13-20 | Initiated | SunTrust | Buy |
| Mar-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-24-20 | Initiated | Berenberg | Hold |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-05-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Neutral |
| May-23-19 | Initiated | Stifel | Hold |
| Mar-29-19 | Initiated | Piper Jaffray | Overweight |
View All
Allogene Therapeutics Inc Stock (ALLO) Latest News
Allogene Therapeutics SVP sells $13k in stock - Investing.com
Allogene Therapeutics (ALLO) SVP sells shares in tax-related sell-to-cover - Stock Titan
Chart Watch: What are the future prospects of Allogene Therapeutics Inc2026 Big Picture & Entry Point Strategy Guides - baoquankhu1.vn
Allogene Therapeutics (NASDAQ: ALLO) notice to sell 2,867 shares - Stock Titan
Allogene Therapeutics (NASDAQ:ALLO) Shares Up 11.9%What's Next? - MarketBeat
Why Allogene Therapeutics (ALLO) says its lead cancer program is still on track in 2026 - MSN
ALLO Technical Analysis & Stock Price Forecast - intellectia.ai
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2025 earnings call transcript - MSN
If You Invested $1,000 in Allogene Therapeutics (ALLO) - Stock Titan
Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026 - Yahoo Finance
5 Penny Stocks with Potential to Rise 1000 Percent - Insider Monkey
Risk Check: Will Allogene Therapeutics Inc benefit from geopolitical trends2026 Biggest Moves & Real-Time Buy Zone Alerts - baoquankhu1.vn
Allogene Therapeutics advances CAR T therapy to expand access for patients - Traders Union
Piper Sandler analysts bullish on Allogene Therapeutics (ALLO) ahead of key ALPHA3 data readout - MSN
ALLO Technical Analysis | Trend, Signals & Chart Patterns | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) - chartmill.com
Worthington Steel Posts Downbeat Earnings, Joins MillerKnoll And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Allogene Therapeutics (NASDAQ:ALLO) Upgraded at Truist Financial - MarketBeat
Allogene Therapeutics (NASDAQ:ALLO) Stock Price Down 9.2%Here's Why - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Allogene Therapeutics (NASDAQ:ALLO) Shares Up 11.4%Time to Buy? - MarketBeat
Allogene Therapeutics, Inc.(NasdaqGS:ALLO) added to S&P Biotechnology Select Industry Index - marketscreener.com
Allogene targets pivotal ALPHA3 data in April and extends cash runway into 2028 while prioritizing scalable CAR T programs - MSN
Piper Sandler Analysts Bullish on Allogene Therapeutics (ALLO) Ahead of Key ALPHA3 Data Readout - Insider Monkey
Allogene Therapeutics (NASDAQ:ALLO) SVP Sells $11,942.45 in Stock - MarketBeat
David Chang Sells 47,763 Shares of Allogene Therapeutics (NASDAQ:ALLO) Stock - MarketBeat
Allogene (NASDAQ: ALLO) SVP share sale funds tax withholding - Stock Titan
Allogene (ALLO) CEO executes 47,763-share tax sell-to-cover transaction - Stock Titan
Allogene Therapeutics targets new approach to autoimmune conditions with ALLO-329 - Traders Union
Allogene Therapeutics (NASDAQ:ALLO) Stock Price Down 5.1%Time to Sell? - MarketBeat
Take the Zacks approach to beat the markets: Starbucks, Amgen, Allogene in focus - MSN
Form 144 Allogene Therapeutics For: 16 March By Investing.com - Investing.com Australia
Allogene Therapeutics (NASDAQ: ALLO) proposes sale of 4,835 shares - Stock Titan
Allogene Therapeutics (NASDAQ: ALLO) RSUs Vest, 47,763 Common Shares - Stock Titan
ALLO Stock News Today | Earnings, Events & Price Alerts - intellectia.ai
Citizens reiterates Allogene stock rating on pipeline progress By Investing.com - Investing.com South Africa
Citizens reiterates Allogene stock rating on pipeline progress - Investing.com
Short Interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Expands By 19.8% - MarketBeat
Allogene Therapeutics Banks on 2026 Trial Catalysts - The Globe and Mail
Iovance Biotherapeutics: The High‑Risk Cancer Stock I Think Could Change a Portfolio by 2036 - AOL.com
El Pollo Loco Posts Upbeat Q4 Results, Joins Kyivstar Group, American Public Education And Other Big Stocks Moving Higher On Friday - Sahm
Analysts Are Bullish on Top Healthcare Stocks: Equillium (EQ), Qiagen (QGEN) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Allogene Therapeutics (ALLO) - The Globe and Mail
Allogene Therapeutics Inc Stock (ALLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.49%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):